OBSOLETE: Graft rejection after lung transplantation

Last reviewed

🖨 Print for my doctorAdvocacy Hub →
ORPHA:91128
Who is this for?
Show terms as
1FDA treatments8Treatment centers1Financial resources

Where are you in your journey?

ℹ
UniteRare data is sourced from FDA.gov, ClinicalTrials.gov, Orphanet, OMIM, and NORD.
Report missing data

Overview

Orphanet ↗NORD ↗

Treatments

1 available

Zenapax

Daclizumab· Hoffmann-La Roche, Inc.

Prophylaxis of acute organ rejection in patients receiving renal transplants, to be used as a part of an immunosuppressive regimen that includes cyclosporine and corticosteroids

View Details →Patient Assistance ↗

Clinical Trials

View all trials with filters →

No actively recruiting trials found for OBSOLETE: Graft rejection after lung transplantation at this time.

New trials open frequently. Follow this disease to get notified.

Search ClinicalTrials.gov ↗Join the OBSOLETE: Graft rejection after lung transplantation community →

Specialists

View all specialists →

No specialists are currently listed for OBSOLETE: Graft rejection after lung transplantation.

View NORD Rare Disease Centers ↗Undiagnosed Disease Network ↗

Treatment Centers

8 centers
🏥 NORD

Baylor College of Medicine Rare Disease Center ↗

Baylor College of Medicine

📍 Houston, TX

🏥 NORD

Stanford Medicine Rare Disease Center ↗

Stanford Medicine

📍 Stanford, CA

🔬 UDN

NIH Clinical Center Undiagnosed Diseases Program ↗

National Institutes of Health

📍 Bethesda, MD

🔬 UDN

UCLA UDN Clinical Site ↗

UCLA Health

📍 Los Angeles, CA

🔬 UDN

Baylor College of Medicine UDN Clinical Site ↗

Baylor College of Medicine

📍 Houston, TX

🔬 UDN

Harvard/MGH UDN Clinical Site ↗

Massachusetts General Hospital

📍 Boston, MA

🏥 NORD

Mayo Clinic Center for Individualized Medicine ↗

Mayo Clinic

📍 Rochester, MN

👤 Mayo Clinic Center for Individualized Medicine

🏥 NORD

UCLA Rare Disease Day Program ↗

UCLA Health

📍 Los Angeles, CA

Financial Resources

1 resources
Zenapax(Daclizumab)— Hoffmann-La Roche, Inc.

Travel Grants

No travel grants are currently matched to OBSOLETE: Graft rejection after lung transplantation.

Search all travel grants →NORD Financial Assistance ↗

Community

Open OBSOLETE: Graft rejection after lung transplantationForum →

No community posts yet. Be the first to share your experience with OBSOLETE: Graft rejection after lung transplantation.

Start the conversation →

Latest news about OBSOLETE: Graft rejection after lung transplantation

1 articles
NewsFDA
FDA Approves MYCOPHENOLATE MOFETIL
MYCOPHENOLATE MOFETIL (MYCOPHENOLATE MOFETIL) received FDA approval.
See all news about OBSOLETE: Graft rejection after lung transplantation →

Caregiver Resources

NORD Caregiver Resources

Support, advocacy, and financial assistance for caregivers of rare disease patients.

Mental Health Support

Rare disease caregiving can be isolating. Connect with counseling and peer support.

Family & Caregiver Grants

Financial assistance programs specifically for caregivers of rare disease patients.

Social Security Disability

Learn how rare disease patients may qualify for SSDI/SSI benefits.

Common questions about OBSOLETE: Graft rejection after lung transplantation

What treatment and support options exist for OBSOLETE: Graft rejection after lung transplantation?

1 patient support program are currently tracked on UniteRare for OBSOLETE: Graft rejection after lung transplantation. See the treatments and support programs sections for copay assistance, eligibility, and contact details.